Pardes Biosciences Inc (PRDS)

[crudeoil24]

Pardes Biosciences, Inc., formerly FS Development Corp. II, is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate, PBI-0451, is in clinical development and is developed to treat and prevent coronaviral (CoV) infections. It has built a discovery platform designed to target reactive nucleophiles. By leveraging its knowledge of structure-based drug design, reversible covalent chemistry and viral biology, it has discovered and is developing novel product candidates with low nanomolar potency against SARS-CoV-2 and activity against all known pathogenic human coronaviruses. Its lead product candidate, PBI-0451, inhibits the main coronaviral cysteine protease (Mpro), a viral protein essential for replication of all known coronaviruses, including SARS-CoV-2. PBI-0451 product candidate is in Phase I clinical development.